 RADNOR, Pa., July 6, 2021 PRNewswire -- NRx Pharmaceuticals Nasdaq: NRXP NRx, a clinical stage biopharmaceutical company, today announced it is initiating clinical training of Nation of Georgia Georgia ICU physicians, in the use of intravenous ZYESAMITM Aviptadil- acetate for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMITM for use in phase 23 clinical trials, for patients suffering with COVID-19. 